St Marys Home For The Aged | |
1635 S 21st Street, Manitowoc, Wisconsin 54220 | |
(920) 684-7171 | |
Name | St Marys Home For The Aged |
---|---|
Location | 1635 S 21st Street, Manitowoc, Wisconsin |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 84 |
Occupancy Rate | 49.76% |
Medicare ID (CCN) | 525609 |
Legal Business Name | St. Mary's Home For The Aged, Inc |
Ownership Type | Non Profit - Corporation |
NPI Number | 1609882448 |
Organization Name | ST. MARY'S HOME FOR THE AGED, INC |
Address | 1635 S 21st St, Manitowoc, WI 54220 |
Phone Number | 920-684-7171 |
News Archive
Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted conjugate compound, is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.
Staphylococcus aureus - better known as Staph - is a common inhabitant of the human nose, and people who carry it are at increased risk for dangerous Staph infections.
In recent years, many groups, including policy makers and health systems, have looked for ways to reduce the number of visits to the emergency department (ED) as a way to lower costs and improve the quality of care. Research conducted by Jesse Pines, M.D., director of the Office of Clinical Practice Innovation and professor of emergency medicine at the George Washington University (GW) School of Medicine and Health Sciences, explored interventions that had been implemented outside of EDs that were designed to reduce ED use.
› Verified 5 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted conjugate compound, is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.
Staphylococcus aureus - better known as Staph - is a common inhabitant of the human nose, and people who carry it are at increased risk for dangerous Staph infections.
In recent years, many groups, including policy makers and health systems, have looked for ways to reduce the number of visits to the emergency department (ED) as a way to lower costs and improve the quality of care. Research conducted by Jesse Pines, M.D., director of the Office of Clinical Practice Innovation and professor of emergency medicine at the George Washington University (GW) School of Medicine and Health Sciences, explored interventions that had been implemented outside of EDs that were designed to reduce ED use.
› Verified 5 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 12.18 | 14.46 |
Percentage of long-stay residents who lose too much weight | 5.19 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 80.6 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.59 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 2.99 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 4.09 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 7.6 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 95.79 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 20.82 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 10.76 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 2.63 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.5 | 95.98 |
Percentage of short-stay residents who made improvements in function | 79.78 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 93.35 | 82.93 |
News Archive
Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted conjugate compound, is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.
Staphylococcus aureus - better known as Staph - is a common inhabitant of the human nose, and people who carry it are at increased risk for dangerous Staph infections.
In recent years, many groups, including policy makers and health systems, have looked for ways to reduce the number of visits to the emergency department (ED) as a way to lower costs and improve the quality of care. Research conducted by Jesse Pines, M.D., director of the Office of Clinical Practice Innovation and professor of emergency medicine at the George Washington University (GW) School of Medicine and Health Sciences, explored interventions that had been implemented outside of EDs that were designed to reduce ED use.
› Verified 5 days ago
Bay At North Ridge Health And Rehabilitation Location: 1445 N 7th St, Manitowoc, Wisconsin 54220 Phone: (920) 682-0314 | |
Manitowoc Healthcare Center Location: 2021 S Alverno Rd, Manitowoc, Wisconsin 54220 Phone: (920) 683-4100 | |
River's Bend Health Services Location: 960 S Rapids Rd, Manitowoc, Wisconsin 54220 Phone: (920) 684-1144 | |
Shady Lane Nursing Care Center Location: 1235 S 24th St, Manitowoc, Wisconsin 54220 Phone: (920) 682-8254 | |
St Marys Home For The Aged Location: 1635 S 21st Street, Manitowoc, Wisconsin 54220 Phone: (920) 684-7171 |